Viewing Study NCT00165256



Ignite Creation Date: 2024-05-05 @ 11:54 AM
Last Modification Date: 2024-10-26 @ 9:15 AM
Study NCT ID: NCT00165256
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2023-12-06
First Post: 2005-09-09

Brief Title: Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast
Sponsor: Dana-Farber Cancer Institute
Organization: Dana-Farber Cancer Institute

Study Overview

Official Title: Wide Excision Alone for DCIS-Grades 1 and 2
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2023-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to determine if wide excision surgical removal alone is adequate treatment for small grade 1 or 2 ductal carcinoma in situ DCIS of the breast
Detailed Description: Patients with DCIS are usually treated with the combination of breast-conserving surgery and radiation therapy or breast-conserving surgery alone The purpose of this study is to evaluate whether localized low- or intermediate-grade DCIS diagnosed with modern mammography and careful pathologic evaluation could be treated with wide excision alone omission of radiation therapy and result in acceptably low local recurrence rates
Follow-up consists of physical examinations at least every 6 months by the surgeon or radiation oncologist Mammograms of the affected breast will be obtained every 6 months for 5 years and then annually Mammograms of the unaffected breast will be performed annually

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None